Other authors suggest using GITR-specific agonists after developing antigen-specific T cells, which boost T cell response against tumor antigens, with concomitant use of molecules that block negative signaling (e.g., CTLA4, PD-1) [163]. The gene discussed is TNFRSF18; the disease is neoplasm.